All News

Results from a phase 3 study showed that galcanezumab-gnlm (Emgality, Eli Lilly) significantly improved work productivity and health and well-being between migraine attacks.

Officials with the FDA have granted priority review for mepolizumab (Nucala, GlaxoSmithKline) in the treatment of patients with hypereosinophilic syndrome.

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

In an interview with Drug Topics®, Richard Scholz, chief strategy officer of ERxDirect, explained the prominence of telemedicine during the COVID-19 pandemic and the lasting implications of new technologies during unprecedented times.

New data showed that treatment with hydroxychloroquine was associated with increased mortality in hospitalized patients with COVID-19. 

Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.

Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.

Officials with the FDA have approved Octapharma’s investigational new drug (IND) application for intravenous immune globulin (IVIG) (Human, Octagam 10%) therapy.

A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.

Here's a roundup of the latest coronavirus-related news.

In part 2 of our interview, Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), discussed the results of their recent survey, which found that many pharmacists and pharmacy technicians feel unsafe from COVID-19 at their workplaces.

AstraZeneca has received funds exceeding $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford’s coronavirus disease 2019 (COVID-19) vaccine candidate.

Supplementation during pregnancy can have potential positive health outcomes for offspring.

The US Department of Health & Human Services partners with Phlow Corporation team to prevent drug shortages during the current pandemic and in future public health emergencies.

A new guidance from the US Department of Health & Human Services (HHS) paves the way for pharmacists nationwide to administer coronavirus disease 2019 (COVID-19) tests.

Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), joined Drug Topics® to discuss their recent survey that pinpointed where pharmacists are feeling most unprotected during the pandemic.

Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV. 

Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.

Atezolizumab demonstrated a significant overall survival benefit in individuals with high PD-L1 expression compared with chemotherapy.

The US Department of Health & Human Services has left it up to state health departments to decide how to distribute remdesivir to hospitals.

Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).

Community pharmacies are ideally positioned to support reopening efforts and recovery plans amid the coronavirus disease 2019 pandemic. 

Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.

Moderna’s coronavirus disease 2019 vaccine candidate, mRNA-1273, showed promise in interim data from its phase 1 study.

"I have to admit that in all 39 years of my career as a community pharmacist, I have never seen a drug that was the center of such intense political discussion."

In part 2 of our interview, Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities.

A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.

New digital health products are providing more insight into data and the opportunity for real-time patient interaction.